Nedaplatin API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Nedaplatin API 95734-82-0?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Nedaplatin. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Nedaplatin
- Synonyms:
- (glycolato-O,O')diammineplatinum(II) , CDGP , cis-Diammine (glycolato)platinum , cis-diammine(glycolato)platinum , cis-Diammine(glycolato)platinum(II) , Nedaplatin
- Cas Number:
- 95734-82-0
- DrugBank number:
- DB13145
- Unique Ingredient Identifier:
- 8UQ3W6JXAN
General Description:
Nedaplatin, identified by CAS number 95734-82-0, is a notable compound with significant therapeutic applications. Nedaplatin is a second generation platinum analog . It is less nephrotoxic than but has proven equally effective. It was approved for use in Japan in 1995.
Indications:
This drug is primarily indicated for: Used in the treatment of non-small cell lung cancer, small cell lung cancer, oesophygeal cancer, and head and neck cancers . Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Protein Binding:
Nedaplatin exhibits a strong affinity for binding with plasma proteins: Approximately 50% of the platinum from nedaplatin appears to be bound to human plasma proteins . This property plays a key role in the drug's pharmacokinetics and distribution within the body.
Route of Elimination:
The elimination of Nedaplatin from the body primarily occurs through: Most of the platinum from nedaplatin is eliminated in the urine (59.6%) . Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Volume of Distribution:
Nedaplatin is distributed throughout the body with a volume of distribution of: The volume of distribution of free platinum is 12.0 L . This metric indicates how extensively the drug permeates into body tissues.
Clearance:
The clearance rate of Nedaplatin is a critical factor in determining its safe and effective dosage: Clearance of the free platinum is 4.47 L/h . It reflects the efficiency with which the drug is removed from the systemic circulation.
Pharmacodynamics:
Nedaplatin exerts its therapeutic effects through: Nedaplatin damages DNA and induces cell death in cancer cells . It also functions as a radiosensitizer, increasing the susceptibility of the affected cells to radiation therapy . The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
Nedaplatin functions by: As a platinum analog, nedaplatin likely works similarly to on which the following mechanistic description is based. Once it has entered the cell it is hydrolyzed to its active form which complexes with water molecules . This form binds to to nucleophiles in the cytoplasm such as glutathione and other cyteine rich proteins resulting in an overall increase in oxidative stress as the cell loses antioxidant proteins. It also binds to purine nucleotides in the DNA. The active form allows for two binding interactions to form cross-links between these nucleotides. High mobility group proteins-1 and -2 induce apoptosis in response to guanine cross-links and their binding serves to shield the cross-linked DNA from repair mechanisms. The mismatch repair (MMR) protein complex also recognizes the distortion caused by platinum complexes and attempts to repair the DNA. This results in single strand breaks when the MMR complex attempts to remove the platinum cross-link. The MMR complex induces apoptosis after the repair attempt has failed. The single strand break in DNA makes it easier to form lethal double strand breaks with radiation treatment thus creating the radiosensitizing effect of nedaplatin . This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Toxicity:
Classification:
Nedaplatin belongs to the class of organic compounds known as carboxylic acid salts. These are ionic derivatives of carboxylic acid, classified under the direct parent group Carboxylic acid salts. This compound is a part of the Organic compounds, falling under the Organic acids and derivatives superclass, and categorized within the Carboxylic acids and derivatives class, specifically within the Carboxylic acid derivatives subclass.
Categories:
Nedaplatin is categorized under the following therapeutic classes: Antineoplastic Agents, Drugs that are Mainly Renally Excreted, Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Narrow Therapeutic Index Drugs, Organometallic Compounds, Platinum Compounds. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Experimental Properties:
Further physical and chemical characteristics of Nedaplatin include:
- Water Solubility: 10 mg/mL
Nedaplatin is a type of Antineoplastics
Antineoplastics are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) primarily used in the treatment of cancer. These powerful substances inhibit or destroy the growth of cancer cells, thus impeding the progression of malignancies.
Antineoplastics exert their therapeutic effects through various mechanisms. Some APIs interfere with DNA replication, inhibiting the division and proliferation of cancer cells. Others target specific proteins or enzymes involved in tumor growth, effectively blocking their function. Additionally, certain antineoplastic agents induce programmed cell death, known as apoptosis, in cancer cells.
These APIs find application in a wide range of cancer treatments, including chemotherapy, targeted therapy, immunotherapy, and hormone therapy. They are often administered in combination with other drugs to optimize therapeutic outcomes and minimize drug resistance.
Antineoplastics are typically synthesized through complex chemical processes, ensuring high purity and potency. Stringent quality control measures are implemented throughout manufacturing to meet regulatory standards and ensure patient safety.
Although antineoplastics offer significant benefits in treating cancer, they can also cause adverse effects due to their cytotoxic nature. Common side effects include bone marrow suppression, gastrointestinal disturbances, hair loss, and immune system suppression. Close monitoring and supportive care are essential to manage these side effects effectively.
In conclusion, antineoplastics are a vital category of pharmaceutical APIs used in the treatment of cancer. Through their diverse mechanisms of action, these compounds play a critical role in combating malignancies and improving patient outcomes.
